BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.
BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.